vivitrol: Clinical Trials

77 trials of vivitrol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

62 completed, 11 terminated, 2 active not recruiting, 1 unknown. 27 Phase 3, 26 Phase 2, 20 Phase 4, 9 Phase 1, 3 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 327Completed 23, Terminated 2, Active not recruiting 1, Unknown 1
Phase 226Completed 17, Terminated 7, Active not recruiting 1, Unknown 1
Phase 420Completed 17, Terminated 2, Withdrawn 1
Phase 19Completed 8, Terminated 1
Not applicable3Completed 3
Early Phase 11Completed 1

Follow vivitrol: new trials by email Literature Review of vivitrol trials Research Report on vivitrol

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia
Naltrexone (Vivitrol), Bupropion - Smoking Cessation
Phase 1TerminatedThe University of Texas Health Science Center, Houston22024-07-162025-09-16
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB - Methamphetamine-dependence, Methamphetamine Abuse
Phase 3Active not recruitingNational Institute on Drug Abuse (NIDA)3602024-07-012026-07-13
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep
Lemborexant 10 mg, Naltrexone - Alcohol Use Disorder
Phase 3CompletedBaylor College of Medicine82023-02-092026-03-24
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
Methadone, Buprenorphine/naloxone, XR-Naltrexone - Opioid-use Disorder, HIV-1-infection
Phase 2TerminatedUniversity of Pennsylvania782023-01-302026-04-07
Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder
Brixadi, Vivitrol - Opioid Dependence
Phase 2TerminatedUniversity of Pennsylvania32022-08-012025-08-06
Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections
BICX104, Vivitrol - Opioid-use Disorder
Phase 1CompletedBioCorRx Inc242022-06-172023-08-16
In Hospital IM Naltrexone: A Pilot Study
injectable naltrexone, oral naltrexone - Alcohol Use Disorder
Phase 4WithdrawnUniversity of Colorado, Denver2022-03-012023-04-07
Vivitrol Treatment for Cannabis Use Disorder
Naltrexone 380 MG [Vivitrol], Motivational Enhancement Therapy and Cognitive Behavioral Therapy - Cannabis Use Disorder
Phase 2TerminatedCentre for Addiction and Mental Health12021-06-092025-02-07
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
SL-BUP, XR-BUP, XR-NTX - Opioid Use Disorder (OUD)
Phase 2Active not recruitingNYU Langone Health15162021-06-082026-11-10
Impact of Colchicine and Low-dose Naltrexone on COVID-19
Colchicine 0.6 mg, Naltrexone - Covid19
Phase 2CompletedHealthPartners Institute1422021-01-252023-07-25
Pharmacokinetic Study of Vivitrol in Healthy Participants
Naltrexone 380 MG - Opioid-use Disorder
Phase 1CompletedGo Medical Industries Pty Ltd92021-01-252024-02-23
Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults
XR-B (SUBLOCADETM), XR-NTX - Opioid-use Disorder
Phase 4CompletedNYU Langone Health6752021-01-072025-05-14
Emergency Department Initiated Extended-Release Naltrexone and Case Management for the Treatment of Alcohol Use Disorder
Vivitrol (Extended Release Naltrexone) - Alcohol Use Disorder, Substance Use
Phase 4TerminatedUniversity of California, San Francisco1792020-08-142023-06-22
Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
Naltrexone, Ketamine, Placebo - COVID-19, Acute Respiratory Distress Syndrome
Phase 2TerminatedCorewell Health East702020-04-292022-01-26
Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder
XR-NTX community location - Opioid Dependence
Early Phase 1CompletedMichele Staton92019-09-112023-03-27
Medication Maintenance Therapy in Community Pharmacy Settings
buprenorphine/naloxone oral product, injectable naltrexone, Pharmacy maintenance addiction care - Opioid-use Disorder
Phase 2 / Phase 3UnknownLifespan2502019-07-252022-08-24
Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD
2mg Buprenex and 380mg Vivitrol, Placebo (SL pill qd, IM injection q4weeks) - Post Traumatic Stress Disorder, Alcohol Abuse
Phase 2TerminatedPharmacotherapies for Alcohol and Substance Use Disorders Alliance692019-05-202023-09-14
Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery
Extended release naltrexone - Opioid-use Disorder
Phase 4CompletedLars Tanum3172018-08-012022-12-02
Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
Naltrexone for extended-release injectable suspension, Oral naltrexone - Opioid-Related Disorders
Phase 4CompletedDuke University142017-09-212020-06-16
A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
Vivitrol, Buprenorphine - Opioid-use Disorder
Phase 3CompletedNew York State Psychiatric Institute112017-08-012022-11-07

Showing 20 of 77. Sign in to see all of them.

Conditions studied

Opioid-Related Disorders (39)  ·  Alcoholism (23)  ·  Substance-Related Disorders (9)  ·  Behavior, Addictive (7)  ·  Heroin Dependence (6)  ·  Acquired Immunodeficiency Syndrome (3)  ·  Amphetamine-Related Disorders (2)  ·  COVID-19 (2)  ·  Cocaine-Related Disorders (2)  ·  Emergencies (2)  ·  Inflammation (2)  ·  Stress Disorders, Post-Traumatic (2)  ·  Alcohol Drinking (1)  ·  Alcohol-Related Disorders (1)  ·  Cardiovascular Diseases (1)

Sponsors

Alkermes, Inc. (10)  ·  University of Pennsylvania (9)  ·  NYU Langone Health (8)  ·  New York State Psychiatric Institute (8)  ·  Yale University (5)  ·  University of California, Los Angeles (3)  ·  National Institute on Drug Abuse (NIDA) (2)  ·  Oregon Health and Science University (2)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Baylor College of Medicine (1)  ·  BioCorRx Inc (1)  ·  Boston University (1)  ·  Brown University (1)  ·  California Pacific Medical Center Research Institute (1)  ·  Centre for Addiction and Mental Health (1)

Countries

United States (60)  ·  Russia (3)  ·  Canada (2)  ·  Norway (2)  ·  Iceland (1)  ·  Lithuania (1)  ·  Netherlands (1)  ·  Vietnam (1)

Top investigators

Bernard L. Silverman, MD (4)  ·  Adam Bisaga, MD (2)  ·  Bernard L Silverman, MD (2)  ·  Daniel Langleben, MD (2)  ·  George E Woody, MD (2)  ·  John Rotrosen, MD (2)  ·  Lars Tanum, MD, PhD (2)  ·  Philip T Korthuis, MD, MPH (2)  ·  Sandra A Springer, MD (2)  ·  Adam Bisaga, M.D. (1)  ·  Alexander Okhapkin, Prof. (1)  ·  Alexander Sofronov, Prof. (1)  ·  Alexey Egorov, Prof. (1)  ·  Allison G Robertson, PhD, MPH (1)

Results publications

PMID 40342086, PMID 15811981, PMID 24674234, PMID 26560326, PMID 32379516, PMID 10553740, PMID 11707638, PMID 1334156, PMID 1345133, PMID 1444726, PMID 16223067, PMID 16624967, PMID 17045423, PMID 17588491, PMID 17873686, PMID 18241321, PMID 18348601, PMID 18472999, PMID 18775624, PMID 19053979, PMID 20363090, PMID 21314752, PMID 21529928, PMID 21575016, PMID 21715107, PMID 21769033, PMID 22089316, PMID 22945623, PMID 22985676, PMID 23036218, PMID 23159524, PMID 23188075, PMID 23571420, PMID 23577900, PMID 23627868, PMID 23701526, PMID 24650044, PMID 24825644, PMID 25037206, PMID 25092008, PMID 25703440, PMID 25901451, PMID 26039070, PMID 26629534, PMID 26948856, PMID 27121539, PMID 27178765, PMID 27282118, PMID 27521809, PMID 28061017

NIH funding

P50DA012756 (2), R01DA010746 (2), UG1DA013035 (2), 2009 (1), 2017 (1), K02DA032322 (1), K23AA022989 (1), R01AA018923 (1), R01AA018944 (1), R01AA021335 (1), R01AA021744 (1), R01DA015822 (1), R01DA019497 (1), R01DA024549 (1), R01DA027405 (1)